Navigating The Blood-Brain Barrier: An Interview With AngioChem CEO Jean-Paul Castaigne
This article was originally published in The Pink Sheet Daily
Executive Summary
Castaigne talks about combining AngioChem’s proprietary technology with cytotoxins, mAbs, siRNA and peptides to create therapies for cancer and neurodegenerative diseases and, oh yes, to solve the obesity problem.
You may also be interested in...
With Geron Deal Done, AngioChem Turns To Its Own Pipeline
A $35 million agreement gets Geron a cancer drug that can cross the blood brain barrier - and gives AngioChem financial runway for its own pursuits.
With Geron Deal Done, AngioChem Turns To Its Own Pipeline
A $35 million agreement gets Geron a cancer drug that can cross the blood brain barrier - and gives AngioChem financial runway for its own pursuits.
Back To School: Catch Up On Our Executive Interviews
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.